Direct Link:
1523-4681/asset/olbannerleft.gif?v=1&s=d7e4c0e37904a489128d3a4e58ba94214db307a9)
1523-4681/asset/olbannerright.gif?v=1&s=854ee0e4d351ead9faaca8bfab3e50b1c7c9d03d)
Original Article
You have full text access to this OnlineOpen article
Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis
Article first published online: 14 JAN 2010
DOI: 10.1002/jbmr.16
Copyright © 2010 American Society for Bone and Mineral Research
Additional Information
How to Cite
Kelly, T., Suva, L. J., Nicks, K. M., MacLeod, V. and Sanderson, R. D. (2010), Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis. J Bone Miner Res, 25: 1295–1304. doi: 10.1002/jbmr.16
Publication History
- Issue published online: 27 MAY 2010
- Article first published online: 14 JAN 2010
- Accepted manuscript online: 14 JAN 2010 12:00AM EST
- Manuscript Accepted: 29 DEC 2009
- Manuscript Revised: 28 DEC 2009
- Manuscript Received: 12 AUG 2009
References
- 1, . Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer. 2003; 97: 834–839.
- 2, , , et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest. 1996; 98: 1544–1549.
- 3, , , et al. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res. 2002; 62: 5571–5579.
- 4, , , et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003; 3: 537–549.
- 5, , . Mechanisms of bone metastases of breast cancer. Endocr Relat Cancer. 2009; 16: 703–713.
- 6. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2: 584–593.
- 7, , , et al. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res. 2005; 65: 7682–7690.
- 8, , , et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009; 360: 679–691.
- 9, , . Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol. 2006; 38: 2018–2039.
- 10, , , , , . Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes. J Am Coll Surg. 2005; 200: 328–335.
- 11, , , et al. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res. 2003; 63: 8749–8756.
- 12, , , et al. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Res. 2005; 65: 5778–5784.
- 13, , , , . Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res. 1999; 59: 3433–3441.
- 14, , , et al. Mammalian heparanase as mediator of tumor metastasis and angiogenesis. Isr Med Assoc J. 2000; 2 (Suppl): 37–45.
- 15, , , et al. Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol. 2002; 12: 121–129.
- 16, , , et al. Heparanase as mediator of angiogenesis: mode of action. FASEB J. 2001; 15: 1661–1663.
- 17
- 18, , , , , , Cancer cell heparanase activity associated with invasion and metastasis. Adv Enzyme Regul. 1998; 38: 19–32.
- 19
- 20, , , et al. Regulation of heparanase gene expression by estrogen in breast cancer. Cancer Res. 2003; 63: 8821–8826.
- 21, , , et al. Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. Br J Cancer. 2008; 98: 1993–1998.
- 22, , , et al. Expression of syndecan-1 in paired samples of normal and malignant breast tissue from postmenopausal women. Anticancer Res. 2007; 27: 3045–3050.
- 23, . Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis. 2008; 25: 149–159.
- 24, , . The syndecan-1 ectodomain regulates αVβ3 integrin activity in human mammary carcinoma cells. J Cell Biol. 2004; 167: 171–181.
- 25, , , . Syndecan-1 regulates αVβ3 and αVβ5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J Exp Med. 2009; 206: 691–705.
- 26, , , . Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am J Clin Pathol. 1999; 112: 377–383.
- 27, , , , . Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol. 2001; 14: 1052–1058.
- 28, , , . Membrane type 1 matrix metalloproteinase-mediated stromal syndecan-1 shedding stimulates breast carcinoma cell proliferation. Cancer Res. 2008; 68: 9558–9565.
- 29, , , et al. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem. 2007; 282: 13326–13333.
- 30, , , . Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation. J Biol Chem. 2007; 282: 14906–14915.
- 31, , , , , . Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J Cell Biochem. 2005; 96: 897–905.Direct Link:
- 32, , , , , . Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone. 2003; 33: 28–37.
- 33, , , et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-κB ligand pathway. Cancer Res. 2005; 65: 11001–11009.
- 34, , , et al. Cloning, expression, and purification of mouse heparanase. Protein Expr Purif. 2002; 26: 425–431.
- 35, , , et al. Cloning and functional expression of a human heparanase gene. Biochem Biophys Res Commun. 1999; 261: 183–187.
- 36, , , , . Decalcified bone: twenty years of successful specimen management. J Histotechnol. 1997; 20: 267–277.
- 37, , , et al. Interleukin-1 and tumor necrosis factor antagonists attenuate ethanol-induced inhibition of bone formation in a rat model of distraction osteogenesis. J Pharmacol Exp Ther. 2002; 303: 904–908.
- 38. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nature reviews Cancer. 2003; 3: 453–458.
- 39, , . Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Res. 2004; 64: 612–621.
- 40, , , et al. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis. 2009; 30: 397–407.
- 41, , , et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood. 2002; 100: 610–617.
- 42, , , . Syndecan-1 regulates αVβ5 integrin activity in B82L fibroblasts. J Cell Sci. 2006; 119: 2445–2456.
- 43. Bone resorption by osteoclasts. Science. 2000; 289: 1504–1508.
- 44, , , , , . Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis. 2003; 20: 413–420.
- 45, , , et al. A small molecule antagonist of the α(v)β3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin Exp Metastasis. 2004; 21: 119–128.
- 46, . The clinical course of bone metastases from breast cancer. Br J Cancer. 1987; 55: 61–66.
- 47. Mechanisms of bone metastasis. N Engl J Med. 2004; 350: 1655–1664.
- 48, , , et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005; 23: 4925–4935.
- 49, , , . Heparanase: Busy at the cell surface. Trends Biochem Sci. 2009; 34: 511–519.
- 50, , , et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood. 2002; 100: 3002–3007.
- 51, , , . Heparin potentiates in vivo neutrophil migration induced by IL-8. Glycoconj J. 1998; 15: 523–526.
- 52, , , et al. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest. 2000; 105: 433–440.